pegcetacoplan sold brand name empaveli among others medication used treat paroxysmal nocturnal abstract geographic atrophy pegcetacoplan complement common side effects include injectionsite reactions infections diarrhea abdominal pain respiratory tract infection viral infection paroxysmal nocturnal hemoglobinuria characterized red blood cell destruction anemia red blood cells unable carry enough oxygen tissues blood clots impaired bone marrow function making enough blood pegcetacoplan first treatment paroxysmal nocturnal hemoglobinuria binds inhibits complement protein pegcetacoplan approved medical use united states may us food drug administration fda considers firstinclass pegcetacoplan indicated treat adults paroxysmal nocturnal recommended dosage mg administered twice week february indication updated include treatment people geographic atrophy secondary agerelated macular medication given subcutaneous infusion paroxysmal nocturnal hemoglobinuria intravitreal injection agerelated macular pegcetacoplan acts complement inhibitor specifically targeting complement protein plays crucial role pathogenesis paroxysmal nocturnal hemoglobinuria pnh individuals pnh heightened uninhibited complement activity may lead intravascular inside blood vessels extravascular within liver spleen binding inhibiting pegcetacoplan helps regulate complement activation thereby reducing red blood cell destruction anemia blood clot formation improving bone marrow function targeted mechanism action makes pegcetacoplan firstinclass medication treatment pnh offering promising therapeutic approach address underlying complement dysregulation pegcetacoplan exhibits proportional exposure increasing doses reaches peak concentration within days single subcutaneous dose steadystate concentrations achieved weeks treatment average serum trough concentrations ranging µgml pegcetacoplan metabolized smaller peptides amino acids median effective elimination halflife approximately days patients meningococcal type bacteria infections occur people taking pegcetacoplan may also predispose individuals serious infections especially infections caused encapsulated infections include limited streptococcus pneumoniae neisseria meningitidis haemophilus common adverse effects associated medication include stomach pain vomiting diarrhea cold sores commoncold like symptoms tiredness well itching redness sensitivity injection pegcetacoplan may cause fetal pegcetacoplan may also interfere silica reagents laboratory coagulation therapeutic efficacy subcutaneous pegcetacoplan treating paroxysmal nocturnal hemoglobinuria pnh established several clinical trials initial phase ii trials paddock palomino pharoah evaluated pegcetacoplan pnh patients received complement inhibitor previously received eculizumab trials demonstrated years pegcetacoplan treatment effectively controlled hemolysis improved quality life pnh building upon findings efficacy pegcetacoplan assessed phase iii trials prince trial study focused complement inhibitornaïve patients pnh pegasus trial multinational study included complement inhibitortreated patients pnh trials subcutaneous pegcetacoplan administered dosage mg twice weekly delivered subcutaneous infusion patients option selfadminister medication administered qualified research fda granted application pegcetacoplan orphan drug october committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting marketing authorization medicinal product aspaveli intended treatment adults paroxysmal nocturnal applicant medicinal product swedish orphan biovitrum ab pegcetacoplan approved medical use european union december article incorporates public domain material united states department health human services httpsenwikipediaorgwikipegcetacoplan